| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse e... |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Degrading Proteins, Making Medicines MRT-8102 GFORCE-1 Clinical Study Results October 1, 2026 Exhibit 99.2 |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 16, 2026, the record date for the Annual Meeting, there were 84,382,573 outstanding shares o... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 |
| 17 Mar 2026 |
8-K: Results of Operations and Financial Condition
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 |
| 10 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 9, 2026, Edmund Dunn informed us of his intent to retire from the role of SVP, Corporate Controller and Principal Accounting Officer of Monte Rosa Therapeutics, Inc. (the “Company”), effective as of April 3, 2026. Mr. Dunn’s r... |
| 09 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Pre-Funded Warrants to Purchase 1,375,000 Shares of Common Stock |
| 07 Jan 2026 |
8-K: Other Events
Effective January 7, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) terminated the sales agreement prospectus (the “ATM Prospectus”) filed with the Company’s registration statement on Form S-3 (File No. 333-285942) (the “Registratio... |
| 07 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects |
| 16 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tier... |
| 15 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Novartis receives an exclusive license to an undisclosed discovery target |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 ... |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 13, 2025, Monte Rosa Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 16, 2025, the record date for the Annual Meeting, there were 61,509,821 outstanding shares o... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases |
| 20 Mar 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs |
| 10 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | January 2025 |
| 13 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 11, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Monte Rosa Therapeutics, Inc. (the “Company”), the Board appointed Eric A. Hughes, M.D., Ph.D. ... |
Loading...